“I don’t think we want to end up with a
‘NICE-type’ system in France. Because. . .from the public health
point of view, the NICE-type cost per QALY threshold approach
is not appropriate. . . if we don’t think a little bit more in terms
of public health benefits, we are going to have problems. . .you
still have to defend the interests of patients and also integrate
the medical and economic criteria.